Fig. 3: HCC patients with the C16+C18 cluster might be the target population of our novel triple-drug therapy. | Cell Death & Disease

Fig. 3: HCC patients with the C16+C18 cluster might be the target population of our novel triple-drug therapy.

From: Synergistic immunochemotherapy targeted SAMD4B-APOA2-PD-L1 axis potentiates antitumor immunity in hepatocellular carcinoma

Fig. 3

a, c, e, g The tSNE plots of the DMSO group compared with the single-agent and combined-agent groups separately. b, d, f, h The fraction of cells in the DMSO group compared with the single-agent and combined-agent groups separately. Only the C16+C18 cluster was the main target cell cluster of TCC. SAMD4B was the most significantly differentially expressed gene in DMSO vs. TC (i) and DMSO vs. TCC (j). k, l The expression of SAMD4B in the DMSO, TC and TCC groups gradually increased. Differentially expressed gene analysis of DMSO vs. THA (m), DMSO vs. CAN (n), and DMSO vs. CAR (o). p There were 58 differentially expressed genes shared by the three compared groups, and APOA2 was the most significant gene.

Back to article page